Kaposi's sarcoma in rheumatic diseases
- PMID: 12701043
- DOI: 10.1053/sarh.2002.50000
Kaposi's sarcoma in rheumatic diseases
Abstract
Objective: To review the clinical features and outcome of all reported cases of Kaposi's sarcoma in patients with rheumatic diseases.
Methods: In addition to our patient, we identified cases from a Medline search between the years 1966 and 2002. Cases associated with human immunodeficiency virus infection were excluded.
Results: Including our patient, there were a total of 25 cases reported (11 men and 14 women). Rheumatoid arthritis was present in 8 cases, polymyositis/dermatomyositis in 5, vasculitis syndromes in 5, systemic lupus erythematosus in 3, polymyalgia rheumatica in 2, and 1 each of undifferentiated connective tissue disease and Behcet disease. All but 1 patient had been given systemic corticosteroids for a duration that ranged from 6 weeks to 22 years, and immunosuppressive drugs from 25 days to 3.5 years. The Kaposi's lesions usually involved the skin on the extremities; internal organ involvement occurred in 7 cases. Most lesions responded to a decreasing dosage of corticosteroids and immunosuppressive drugs, or to the administration of radiation or cytotoxic therapy. Six patients died, 4 of which were related to the progression of Kaposi's sarcoma.
Conclusion: Kaposi's sarcoma in patients with rheumatologic conditions is rare. The clinical features are similar to those with classical Kaposi's sarcoma. Tumor regression usually occurs with decreasing corticosteroids and/or immunosuppressive drugs, local irradiation, or cytotoxic therapy.
Copyright 2003, Elsevier Inc. All rights reserved.
Comment in
-
The occurrence of Kaposi's sarcoma (KS) in rheumatic diseases.Semin Arthritis Rheum. 2004 Apr;33(5):352; author reply 352-3. Semin Arthritis Rheum. 2004. PMID: 15079765 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
